| Ytd | 14.29% | |
| 1y | -13.00% |
| Open | 12.03 | Prev Close | 12.18 | Low | 12.00 | High | 12.28 | Mkt Cap | 136.46M |
| Vol | 74.35K | Avg Vol | 208.83K | EPS | -2.33 | P/E | N/A | Forward P/E | 56.17 |
| Beta | 0.65 | Short Ratio | 7.68 | Inst. Own | 86.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 09-18 | Earning | 11-09 | 50-d Avg | 10.99 | 200-d Avg | 11.15 | 1yr Est | 16.50 |
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Meta
MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing G
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflecte
Great Lakes Advisors LLC purchased a new position in shares of Medifast Inc (NYSE: MED) in the undef
MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp
MED's improving coach productivity and client retention point to stabilization, but a shrinking coac
Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach bas
Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations supp
Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue
Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown ag
MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pre
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year ear
Medifast (MED) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate
Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market ses
Medifast (NYSE:MED) is looking for Q3 GAAP EPS of $(0.65)-$(0.15) vs $(0.62) analyst estimate. sees
Medifast (NYSE:MED) reported quarterly losses of $(0.28) per share which beat the analyst consensus
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its scie
MED's Q2 results are likely to face continued pressure from GLP-1 adoption and a smaller coach base,
Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known fo
Medifast's Trilivy expands beyond weight management with metabolic health support, personalized coac
The leading health and wellness company unveils an evolutionary transformation from weight loss to o
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comp
Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.
Medifast (NYSE:MED) is looking for Q2 GAAP EPS of $(1.00)-$(0.50) vs $(0.43) analyst estimate. sees
Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus
Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed,
Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is a
Stephens & Co. analyst Jim Salera maintains Medifast (NYSE:MED) with a Equal-Weight and lower
Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide conti
Medifast (NYSE:MED) reported quarterly earnings of $0.22 per share which beat the analyst consensus
Medifast (NYSE:MED) Q3 expected to be more than $(0.60) vs $(0.30) Est. sees Q3 sales of $70.000 mi
Medifast (NYSE:MED) Q2 expected to be more than $(0.55) vs $(0.08) Est. sees Q2 sales of $85.000 mi
Medifast (NYSE:MED) reported quarterly losses of $(0.07) per share which beat the analyst consensus
DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Neutral and lowers t
All three major U.S. indices are red in Wednesday's midday trading as investors weighed Presiden
Medifast (NYSE:MED) Q1 expected to be more than $(0.50) vs $(0.19) Est. sees Q1 sales of $100.000 m